Black Rock Inc. Cerevel Therapeutics Holdings, Inc. Call Options Transaction History
Black Rock Inc.
- $4.23 Trillion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CERE
# of Institutions
227Shares Held
150MCall Options Held
939KPut Options Held
961K-
Bain Capital Investors LLC Boston, MA65.7MShares$2.71 Billion61.94% of portfolio
-
Perceptive Advisors LLC New York, NY10.8MShares$445 Million9.58% of portfolio
-
Avoro Capital Advisors LLC New York, NY7.56MShares$312 Million3.85% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.46MShares$308 Million0.01% of portfolio
-
State Street Corp Boston, MA3.53MShares$145 Million0.01% of portfolio
About Cerevel Therapeutics Holdings, Inc.
- Ticker CERE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 155,752,000
- Market Cap $6.42B
- Description
- Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...